SRP 4053 - Sarepta Therapeutics

Drug Profile

SRP 4053 - Sarepta Therapeutics

Alternative Names: Exon 53 PMO; SRP-4053

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sarepta Therapeutics
  • Class Antisense oligonucleotides; Morpholines
  • Mechanism of Action Dystrophin expression modulators; Genetic transcription inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Duchenne muscular dystrophy

Most Recent Events

  • 06 Sep 2017 Interim efficacy data from a phase I/II trial in Duchenne muscular dystrophy released by Sarepta Therapeutics
  • 18 Jul 2017 Sarepta Therapeutics and BioMarin Pharmaceutical execute a global settlement and a license agreement resolving exon skipping patent litigation
  • 18 Jul 2017 Sarepta Therapeutics and BioMarin Pharmaceutical execute a settlement agreement to resolve global patent proceedings regarding Sarepta’s sale of eteplirsen and future Duchenne muscular dystrophy exon-skipping products
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top